Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives

At the clinical level the role of immunotherapy in cancer is currently at a pivotal point. Therapies such as checkpoint inhibitors are being approved at many levels in cancers such as non-small cell lung cancer (NSCLC). Mesothelioma is a rare orphan disease associated with prior exposure to asbestos...

Full description

Saved in:
Bibliographic Details
Published inTranslational lung cancer research Vol. 9; no. S1; pp. S100 - S119
Main Authors Gray, Steven G., Mutti, Luciano
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 01.02.2020
Subjects
Review
Checkpoint inhibitors
vaccine
co-stimulatory
biomarkers
immunotherapy
mesothelioma
dendritic cell
Online AccessGet full text

Cover

More Information
Summary:At the clinical level the role of immunotherapy in cancer is currently at a pivotal point. Therapies such as checkpoint inhibitors are being approved at many levels in cancers such as non-small cell lung cancer (NSCLC). Mesothelioma is a rare orphan disease associated with prior exposure to asbestos, with a dismal prognosis. Various clinical trials for checkpoint inhibitors have been conducted in this rare disease, and suggest that such therapies may play a role as a treatment option for a proportion of patients with this cancer. Most recently approved as a salvage therapy in mesothelioma was granted in Japan, regulatory approval for their use in the clinic elsewhere lags. In this article we review the current pertinent clinical trials of immunotherapies in malignant mesothelioma, discuss the current issues that may affect the clinical outcomes of such therapies and further evaluate potential candidate new avenues that may become future targets for immunotherapy in this cancer.
Bibliography:Contributions: (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
ISSN:2218-6751
2226-4477
DOI:10.21037/tlcr.2019.11.23